Ascendis Pharma A/S's (ASND) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating restated by research analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They currently have a $170.00 price target on the biotechnology company's stock. Cantor Fitzgerald's target price suggests a potential upside of 21.80% from the company's current price.

Other equities analysts have also issued research reports about the company. Stifel Nicolaus began coverage on Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a "buy" rating and a $200.00 price target for the company. Jefferies Financial Group raised their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research report on Tuesday, August 13th. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a "buy" rating in a research note on Tuesday, August 13th. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Thursday, September 5th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $187.08.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded up $20.35 on Monday, hitting $139.57. The stock had a trading volume of 2,913,019 shares, compared to its average volume of 426,889. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The stock has a market cap of $8.13 billion, a price-to-earnings ratio of -14.52 and a beta of 0.63. The business's fifty day moving average price is $132.51 and its 200 day moving average price is $136.47.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently modified their holdings of ASND. Quarry LP raised its position in Ascendis Pharma A/S by 257.1% in the 2nd quarter. Quarry LP now owns 2,500 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 1,800 shares during the last quarter. Algert Global LLC boosted its stake in shares of Ascendis Pharma A/S by 54.6% during the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company's stock worth $297,000 after buying an additional 770 shares during the period. Lighthouse Investment Partners LLC purchased a new position in shares of Ascendis Pharma A/S during the second quarter worth about $2,762,000. Fred Alger Management LLC raised its stake in Ascendis Pharma A/S by 65.0% during the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock valued at $41,879,000 after acquiring an additional 120,952 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new stake in Ascendis Pharma A/S during the 2nd quarter worth approximately $4,931,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.